Time：Auguest 3, 2009, 2:00 PM
Location：Room 406, Biological Building
（Ottawa Institute of Systems Biology, Department of Biochemistry, Microbiology and Immunology,
Faculty of Medicine, University of Ottawa, Canada）
Ph.D. Chemistry, University of Alberta, Edmonton, 1995.
M.Sc., Physical Chemistry, 1991. Université de Montréal, Montréal, 1991.
B.Sc. Chemistry, Université de Montréal, Montréal,1990.
July 04-present: Professor BMI. Tenured
2007-present: Cross-appointed in chemistry.
July 04-present: Director, Ottawa Institute of Systems Biology.
July 02 –July 04: Senior VP of System Biology, MDS-Proteomics.
March 01-July 02: VP Analytical Sciences, MDS- Proteomics.
Dec. 00-March 01: Director of Mass Spectrometry, MDS-Proteomics.
Jan. 00-Dec. 00: Director of Mass Spectrometry and Applied Research, MDS-Ocata.
1998-2000 : Research Officer: National Research Council of Canada.
1997-1998 : Research Scientist: Advisor: Dr. Ruedi Aebersold.
1995-1997 : Postdoctoral Fellow: Advisor: Dr. Ruedi Aebersold.
Canada Research Chair Tier I 2005-2011.
The Pawson-Mann Scientific Ladder 2000.
Mary Louise Imrie Graduate Award, 1993.
Margaret Thompson Memorial Prize in Chemistry, 1992.
Award of Excellence, from the Society of Chemical Industry, 1990.
Proteomics has emerged as a powerful approach for the study of ensembles of proteins. The bulk of these developments have focused on the identification and quantitation of as many proteins as possible from biological samples, regardless of the quantity of starting material, the mixed cell lineages, and the anatomical diversity present in the test samples. Typically, millions or even billions of cells are used for each analysis. For cell culture-based experiments and experiments involving the analysis of organs or large tumors, this approach has been highly successful. However, the quantity of starting material is limited for rare cells, especially those that are difficult to culture or when specific regions of tissues are studied. We have been working over the last decade on developing technologies that improve the processing of proteomic samples with a focus on the study of rare cells. In particular, we have focused our efforts on the development of a technology called the Proteomic Reactor.The microfluidic proteomic reactor greatly simplifies the processing of complex proteomic samples by combining multiple proteomic steps. Rapid extraction and enrichment of proteins from complex proteomic samples or directly from cells are readily performed on the reactor. Furthermore, chemical and enzymatic treatments of proteins are performed in a 50 nL effective volume which results in an increased number of generated peptides. We will discuss the recent development of the integrated and automated proteomic reactor. We will exemplify the potential of this approach for the analysis of two types of rare cells: First, we will discuss the analysis of human embryonic stem cells using this approach. We will also discuss the quantitative analysis of the proteome of the suprachiasmatic nucleus (SCN) a region of the mouse brain that only contains 20,000 neuron cells. Finally, we will present novel proteomic reactors that were developed for the analysis of post-translational modification including glycosylated and phosphorylated proteins.
Contact: Lu Wang